BeOne Medicines: Lymphoma, Mantle-Cell trials
The registry lists 10 Lymphoma, Mantle-Cell studies with BeOne Medicines as lead sponsor. 4 are open to participants now and 3 have results posted.
Phase 1 6Phase 2 8Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingNCT06742996Phase 3
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingNCT06697184Phase 1/2
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT05471843Phase 1/2Results posted
- Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Phase 1/2Results posted
- Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
- Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Phase 3